Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

NCT00286169 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Amrubicin Hydrochloride

Sponsor

Sumitomo Pharma Co., Ltd.